No BP is making an offer until the patent challenge is decided one way or the other .
Then we're going to waiting a long time for a BO, which means it will likely never happen - if Dr. R. insists on going to trial and loses, they'll almost certainly appeal as high as they can, dragging this out for years. Although I guess a BP could have it's lawyers look over the ruling and see if Dr. R. has a chance in hell of winning on appeal, if they think nope, they might rec a BO offer be made - whether the overhang would lower the BO value I don't know.
Hi Kiwi. I read about BP defending, winning, losing, patent challenges all the time so would you say the reason it is different here with Amarin is because we are a one drug pony and a negative outcome could be disastrous whereas large BP have a much more diversified business.
My concern is potential challenges down the road. A never ending story.